Anti-VEGF therapy as adjuvant therapy

Clouds on the horizon?

Bryan Schneider, George W. Sledge

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Anti-angiogenic therapies have demonstrated their value in the setting of advanced cancer, and are being explored for use in micrometastatic disease. Recent preclinical studies suggest that adjuvant anti-vascular endothelial growth factor (VEGF) therapies may increase the risk of metastasis. How concerning are these preclinical studies, and should they affect our willingness to explore anti-VEGF therapy in the adjuvant setting?

Original languageEnglish
Article number303
JournalBreast Cancer Research
Volume11
Issue number3
DOIs
StatePublished - May 18 2009

Fingerprint

Vascular Endothelial Growth Factor A
Therapeutics
Neoplasm Metastasis
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Anti-VEGF therapy as adjuvant therapy : Clouds on the horizon? / Schneider, Bryan; Sledge, George W.

In: Breast Cancer Research, Vol. 11, No. 3, 303, 18.05.2009.

Research output: Contribution to journalArticle

@article{096125ab01e24f29be3c59f54831af87,
title = "Anti-VEGF therapy as adjuvant therapy: Clouds on the horizon?",
abstract = "Anti-angiogenic therapies have demonstrated their value in the setting of advanced cancer, and are being explored for use in micrometastatic disease. Recent preclinical studies suggest that adjuvant anti-vascular endothelial growth factor (VEGF) therapies may increase the risk of metastasis. How concerning are these preclinical studies, and should they affect our willingness to explore anti-VEGF therapy in the adjuvant setting?",
author = "Bryan Schneider and Sledge, {George W.}",
year = "2009",
month = "5",
day = "18",
doi = "10.1186/bcr2250",
language = "English",
volume = "11",
journal = "Breast Cancer Research",
issn = "1465-5411",
publisher = "BioMed Central",
number = "3",

}

TY - JOUR

T1 - Anti-VEGF therapy as adjuvant therapy

T2 - Clouds on the horizon?

AU - Schneider, Bryan

AU - Sledge, George W.

PY - 2009/5/18

Y1 - 2009/5/18

N2 - Anti-angiogenic therapies have demonstrated their value in the setting of advanced cancer, and are being explored for use in micrometastatic disease. Recent preclinical studies suggest that adjuvant anti-vascular endothelial growth factor (VEGF) therapies may increase the risk of metastasis. How concerning are these preclinical studies, and should they affect our willingness to explore anti-VEGF therapy in the adjuvant setting?

AB - Anti-angiogenic therapies have demonstrated their value in the setting of advanced cancer, and are being explored for use in micrometastatic disease. Recent preclinical studies suggest that adjuvant anti-vascular endothelial growth factor (VEGF) therapies may increase the risk of metastasis. How concerning are these preclinical studies, and should they affect our willingness to explore anti-VEGF therapy in the adjuvant setting?

UR - http://www.scopus.com/inward/record.url?scp=69349099114&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69349099114&partnerID=8YFLogxK

U2 - 10.1186/bcr2250

DO - 10.1186/bcr2250

M3 - Article

VL - 11

JO - Breast Cancer Research

JF - Breast Cancer Research

SN - 1465-5411

IS - 3

M1 - 303

ER -